NRX Pharmaceuticals, Inc.
NRXPNRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia.
Table of contents
Earnings
Next report
Aug 17, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia. The company utilizes a dual-track strategy of drug development and direct clinical service delivery through its majority-owned subsidiary, HOPE Therapeutics. Its core value proposition centers on enhancing neuroplasticity by modulating the NMDA receptor through proprietary formulations of ketamine and oral fixed-dose combinations.
A clinical-stage innovator leveraging Fast Track and Breakthrough Therapy designations to disrupt the generic ketamine market and establish a specialized psychiatric clinic network.
Questions, answered.
- What is NRX Pharmaceuticals, Inc.'s market cap?
- NRX Pharmaceuticals, Inc. (NRXP) has a market capitalization of $175.9M and trades on NASDAQ.
- Who are NRX Pharmaceuticals, Inc.'s competitors?
- NRX Pharmaceuticals, Inc.'s key competitors include Johnson & Johnson, Compass Pathways plc, Cyclerion Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does NRX Pharmaceuticals, Inc. partner with?
- NRX Pharmaceuticals, Inc.'s notable partners include Nephron Pharmaceuticals, Inc., Alcami, Osmind, Inc., and others.
- What subsidiaries does NRX Pharmaceuticals, Inc. have?
- NRX Pharmaceuticals, Inc.'s subsidiaries include NeuroRx, Inc., HOPE Therapeutics, Inc., HTX Management Company, LLC, and others.
- Where is NRX Pharmaceuticals, Inc. headquartered?
- NRX Pharmaceuticals, Inc. is headquartered in United States of America. It has been publicly traded since 2021.